Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy

Abstract excerpt

Even though the number of agents that inhibit TGFβ being tested in patients with cancer has grown substantially, clinical benefit from TGFβ inhibition has not yet been achieved. The myriad mechanisms in which TGFβ is protumorigenic may be a key obstacle to its effective deployment; cancer cells frequently employ TGFβ-regulated programs that engender plasticity, enable a permissive tumor microenvironment, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic factors in colorectal cancer
• Share to Pancreatic and Hepatic Oncology Research
• Share to TGF-β signaling in diseases